News|Articles|November 16, 2026

EMA Backs 3-Month Dapivirine Ring for HIV Prevention in Women

Author(s)Matt Hoffman

The EMA issued a positive opinion for a 3-month dapivirine vaginal ring for HIV prevention in women and girls aged 16 and older, cutting annual product costs by nearly 60%.

The European Medicines Agency (EMA) issued a positive scientific opinion for a 3-month dapivirine vaginal ring for HIV prevention in women and adolescent girls aged 16 years and older, according to a Population Council announcement.1 The opinion includes women who are breastfeeding.1 The ring, developed by the Population Council and its affiliate IPM South Africa, requires replacement only 4 times per year instead of 12.1,2

The opinion came through the EMA's EU-Medicines for All procedure and provides a pathway toward regulatory applications in African countries. The monthly dapivirine ring received a positive EMA opinion in July 2020 and holds regulatory approval in 12 African countries.1

"This is an important step towards expanding HIV prevention choices for women," the African Women's HIV Prevention Accountability Board said in a statement.1

IPM 054 Trial Data Behind the 3-Month Dapivirine Ring Opinion

The EMA review included IPM 054 (NCT05416021), a phase 1, open-label, randomized, crossover trial comparing the relative bioavailability of the 2 ring formulations.1,3 The trial enrolled 124 HIV-negative women aged 18 to 45 years at a single site in Bloemfontein, South Africa.3

Each participant completed 2, 90-day treatment periods separated by a 28-day washout. One period used the 25-mg monthly ring (Ring-004), replaced every 30 days, and the other used the 100-mg 3-month ring (Ring-008) continuously for 90 days. The primary outcome compared dapivirine plasma pharmacokinetic parameters between the 2 formulations.3

The 3-month ring was well tolerated and delivered dapivirine at higher levels than the monthly ring, according to the Population Council.1 The organization said these drug levels suggest efficacy at least equal to the monthly ring; this conclusion rests on pharmacokinetic data rather than a direct measure of HIV incidence.2

Secondary outcomes in the trial included dapivirine concentrations in vaginal fluid, genitourinary treatment-emergent adverse events, and effects on vaginal flora, including vaginal pH and bacterial vaginosis.3 Investigators also measured dapivirine released over each 90-day period and residual drug levels in used rings. Most women in the acceptability data said they would be willing to use the longer-acting ring.2

READ MORE: No Safety Concerns With Dapivirine Ring in Third Trimester of Pregnancy

IPM 054 excluded participants who were pregnant or breastfeeding.3 The EMA opinion covers users aged 16 years and older, including breastfeeding women.1 The monthly ring's 2020 opinion applied to women aged 18 years and older.2

Frequently Asked Questions

What is the 3-month dapivirine vaginal ring?

It is a user-controlled vaginal ring releasing dapivirine over 3 months to reduce the risk of HIV acquisition, replaced 4 times per year instead of monthly.

How does dapivirine prevent HIV?

Dapivirine blocks the ability of HIV to replicate inside healthy cells, and the ring releases the drug locally near the cervix.

What data supported the EMA opinion?

The phase 1 IPM 054 crossover trial in 124 South African women showed the 3-month ring was well tolerated and delivered higher dapivirine levels than the monthly ring.

How the Dapivirine Ring Works and What It Means for HIV Prevention Access

The 3-month ring shares the size and shape of the monthly product. After insertion, it sits in the vagina near the cervix and slowly releases dapivirine at the site of potential infection. Dapivirine blocks the ability of HIV to replicate inside healthy cells.2

Moving from 12 rings to 4 rings per year is expected to reduce annual product costs by nearly 60% compared with the unsubsidized cost of the monthly ring. The Population Council will transfer the commercial license for the 3-month ring to Kiara Health, a pharmaceutical manufacturer based in South Africa, to lead market introduction in Africa.1

Kiara Health plans to work with regulators and public health partners on product introduction and possible local manufacturing, according to the release.1 The monthly ring has also received prequalification and a recommendation from the World Health Organization, according to the Population Council.2

The Population Council plans to pursue approvals in sub-Saharan Africa following the EMA opinion and to explore access in other regions.2 Financial terms of the Kiara Health license transfer were not disclosed.1

References
  1. Population Council's three-month HIV prevention product receives positive scientific opinion from European Medicines Agency. News release. Population Council. November 16, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403740/0/en/population-council-s-three-month-hiv-prevention-product-receives-positive-scientific-opinion-from-european-medicines-agency.html
  2. The three-month dapivirine vaginal ring for HIV prevention. Population Council. Accessed November 16, 2026. https://popcouncil.org/project/the-three-month-dapivirine-vaginal-ring-for-hiv-prevention/
  3. Relative bioavailability trial of dapivirine Ring-004 and Ring-008 (IPM 054). ClinicalTrials.gov identifier: NCT05416021. Updated 2024. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT05416021

Related to this article

FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.